FDA Offers PDUFA Waivers for Antiretroviral HIV Drugs

Drug Industry Daily
A A
Innovative antiretroviral HIV drugs may qualify for PDUFA fee waivers or refunds if the fee would be a significant barrier to development, according to new FDA draft guidance aimed at implementing the President’s Emergency Plan for AIDS Relief.

To View This Article:

Login

Subscribe To Drug Industry Daily